Trial Profile
First Line Durvalumab in Patients With PD-L1 Positive, Advanced NSCLC With Performance Status 2 Unsuitable for Combination Chemotherapy. A Multicenter, Single-arm Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Jun 2023 protocol amended excluding pts with severe respiratory symptoms.
- 06 Jun 2023 Results of primary analysis assessing safety and efficacy of durvalumab in patients with advanced non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 30 Jan 2023 Planned End Date changed from 30 Jun 2026 to 30 Sep 2027.